[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
December 1, 1962


Author Affiliations

Redlands, Calif.

JAMA. 1962;182(9):969. doi:10.1001/jama.1962.03050480075019

This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.


To the Editor:—  In The Journal (181:295 [July 28] 1962), in "Five Years Experience with 5-Fluorouracil," the following observation is made by the authors: "With the added experience gained in the treatment of over 1,000 patients, we do not feel there is anything to be gained by discussing with good-risk patients the mortality rate from 5-FU therapy, for the same reason that the well-trained surgeon refrains from discussing mortality rates of cholecystectomy with patients with cholecystitis."The analogy is dangerous, unwise, and philosophically, medicolegally, and scientifically indefensible. Any well-trained surgeon will not refrain from discussing mortality rates of cholecystectomy with patients with cholecystitis. Furthermore, the analogy between cholecystitis, a curable disease, and incurable cancer is poorly drawn.The acceptance of such an observation causes me to wonder how careful editorial scanning may be.